HSBC Holdings’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

HSBC Holdings’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,513	Closed	-$215K	–	3213
2021 Q2	$215K	Sell	1,513 -6,280	-81%	-$709K	﹤0.01%	2723
2021 Q1	$778K	Buy	+7,793	New	+$909K	﹤0.01%	1731
2020 Q2	–	Sell	-1,411	Closed	-$208K	–	2919
2020 Q1	$208K	Buy	1,411 +103	+8%	+$19.9K	﹤0.01%	2274
2019 Q4	$266K	Sell	1,308 -5,972	-82%	-$1.09M	﹤0.01%	2646
2019 Q3	$585K	Buy	+7,280	New	+$618K	﹤0.01%	2240

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

HSBC Holdings's RETA Position: Q3 2021 in Review

HSBC Holdings sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 1,513 shares — an estimated $215K sold.

HSBC Holdings first reported a position in RETA in Q3 2019 and held it in 5 quarters. The position peaked at $778K in Q1 2021. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

HSBC Holdings reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
HSBC Holdings sold 1,513 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $215K.
HSBC Holdings first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 5 quarters.
HSBC Holdings's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $778K in Q1 2021.
181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on HSBC Holdings's 13F filing for Q3 2021, filed 12 Nov 2021.